Vermont CL - Search Results

1

Cross-reactivity of antibodies against PorA after vaccination with a meningococcal B outer membrane vesicle vaccine.

Vermont CL, van Dijken HH, Kuipers AJ, van Limpt CJ, Keijzers WC, van der Ende A, de Groot R, van Alphen L, van den Dobbelsteen GP. Vermont CL, et al. Infect Immun. 2003 Apr;71(4):1650-5. doi: 10.1128/IAI.71.4.1650-1655.2003. Infect Immun. 2003. PMID: 12654777 Free PMC article. Clinical Trial.

2

Serum bactericidal activity and isotype distribution of antibodies in toddlers and schoolchildren after vaccination with RIVM hexavalent PorA vesicle vaccine.

de Kleijn E, van Eijndhoven L, Vermont C, Kuipers B, van Dijken H, Rümke H, de Groot R, van Alphen L, van den Dobbelsteen G. de Kleijn E, et al. Vaccine. 2001 Nov 12;20(3-4):352-8. doi: 10.1016/s0264-410x(01)00371-1. Vaccine. 2001. PMID: 11672897 Clinical Trial.

3

Antibody avidity and immunoglobulin G isotype distribution following immunization with a monovalent meningococcal B outer membrane vesicle vaccine.

Vermont CL, van Dijken HH, van Limpt CJ, de Groot R, van Alphen L, van Den Dobbelsteen GP. Vermont CL, et al. Infect Immun. 2002 Feb;70(2):584-90. doi: 10.1128/IAI.70.2.584-590.2002. Infect Immun. 2002. PMID: 11796586 Free PMC article. Clinical Trial.

4

Bench-to-bedside review: genetic influences on meningococcal disease.

Vermont CL, de Groot R, Hazelzet JA. Vermont CL, et al. Crit Care. 2002 Feb;6(1):60-5. doi: 10.1186/cc1454. Epub 2001 Nov 26. Crit Care. 2002. PMID: 11940267 Free PMC article. Review.

5

Neisseria meningitidis serogroup B: laboratory correlates of protection.

Vermont C, van den Dobbelsteen G. Vermont C, et al. FEMS Immunol Med Microbiol. 2002 Oct 11;34(2):89-96. doi: 10.1111/j.1574-695X.2002.tb00608.x. FEMS Immunol Med Microbiol. 2002. PMID: 12381458 Free article. Review.

6

Recent developments in vaccines to prevent meningococcal serogroup B infections.

Vermont CL, van den Dobbelsteen GP, de Groot R. Vermont CL, et al. Curr Opin Mol Ther. 2003 Feb;5(1):33-8. Curr Opin Mol Ther. 2003. PMID: 12669468 Review.

7

Antibody specificities and effect of meningococcal carriage in icelandic teenagers receiving the Norwegian serogroup B outer membrane vesicle vaccine.

Wedege E, Kuipers B, Bolstad K, van Dijken H, Frøholm LO, Vermont C, Caugant DA, van den Dobbelsteen G. Wedege E, et al. Infect Immun. 2003 Jul;71(7):3775-81. doi: 10.1128/IAI.71.7.3775-3781.2003. Infect Immun. 2003. PMID: 12819059 Free PMC article.

8

Meningococcal serogroup B infections: a search for a broadly protective vaccine.

Vermont CL, van den Dobbelsteen GP. Vermont CL, et al. Expert Rev Vaccines. 2003 Oct;2(5):673-81. doi: 10.1586/14760584.2.5.673. Expert Rev Vaccines. 2003. PMID: 14711328 Free article. Review.

9

PorA-specific differences in antibody avidity after vaccination with a hexavalent Men B outer membrane vesicle vaccine in toddlers and school children.

Vermont CL, Van Dijken HH, De Groot R, Van Alphen L, Van Den Dobbelsteen GP. Vermont CL, et al. Vaccine. 2004 Aug 13;22(23-24):3008-13. doi: 10.1016/j.vaccine.2004.02.014. Vaccine. 2004. PMID: 15297049 Clinical Trial.

10

Porin A-specific antibody avidity in patients who are convalescing from meningococcal B disease.

Vermont CL, van Dijken HH, de Groot R, van den Dobbelsteen GP. Vermont CL, et al. Pediatr Res. 2005 Jul;58(1):149-52. doi: 10.1203/01.PDR.0000156372.13569.08. Epub 2005 Mar 17. Pediatr Res. 2005. PMID: 15774845

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

73 results

Search Page

Filters